POSTN and cancer: Finally, to investigate the role of the POSTN with exon 17 inhibition in both stroma and cancer in vivo, we treated POSTN exon 17 antibody (40, 100, 250, and 600 μg/mice) or control IgG (600 μg/mice) with the MDA-MB 231 human TNBC xenograft model.